文献速递眼底病与葡萄膜炎

初治色素上皮脱离对抗VEGF首次注射的应答:HARBOR试验事后分析

Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该研究为HARBOR三期随机对照试验的事后分析,纳入586例基线存在色素上皮脱离(PED)的初治新生血管性年龄相关性黄斑变性(nAMD)患者,雷珠单抗0.5mg与2.0mg组汇总分析。首次注射后35.5%患者PED扁平化,第2个月累计约一半;PED扁平化与第1个月最佳矫正视力无优势相关,但按需治疗组中首次注射后PED扁平化者24个月内注射次数更少。

要点

  • 初治nAMD伴PED患者首次雷珠单抗注射后35.5%PED扁平化,第2个月再增17.3%。
  • 基线PED高度较低与首次注射后PED扁平化相关(多因素分析)。
  • 按需治疗组中首次注射后PED扁平化者24个月注射次数更少(11.0 vs 14.2)。

核心结论

  • 初治nAMD伴PED患者首次雷珠单抗注射后约三分之一PED扁平化,第二次注射后约一半扁平化,但PED扁平化者视力结局未更优。
  • PED扁平化可能作为按需治疗中较低注射频率的标记。

研究设计与样本

  • HARBOR三期随机双盲多中心阳性对照试验的事后分析,纳入基线有PED的初治中心凹下nAMD患者,雷珠单抗0.5mg与2.0mg组汇总分析(n=586)。

主要发现

  • 首次雷珠单抗注射后35.5%(208/586)基线PED患者PED扁平化,第2个月另17.3%扁平化。
  • 单因素分析显示年龄较大、PED高度较低、视网膜下液厚度较低与首次注射后PED扁平化相关;多因素分析显示PED高度是与该解剖结局相关的因素。
  • 第1个月PED扁平化与否,最佳矫正视力评分无优势。
  • 按需治疗组中首次注射后PED扁平化者24个月内平均注射次数少于第1个月PED仍存在者(11.0 vs 14.2;差值3.3;95%CI 1.9-4.6;P<.001)。

临床怎么用

  • 对初治nAMD伴PED患者,首次抗VEGF注射后PED扁平化可提示按需治疗方案下可能需要较少注射次数。
  • PED扁平化不宜作为视力获益的替代指标,视力随访仍需独立评估。

局限性

  • 本文为事后分析,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pigment epithelial detachment (PED) is a feature commonly associated with neovascular age-related macular degeneration (nAMD) and may be perceived as being difficult to treat. Therefore, this investigation explored changes in PEDs and visual acuity outcomes following an initial anti-vascular endothelial growth factor (VEGF) injection and identified factors associated with positive response. OBJECTIVE: To describe changes in treatment-naive pigment epithelial detachments associated with the initial anti-VEGF injection. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of patients from the Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR) trial (NCT00891735) with PED at baseline. The HARBOR trial was a phase 3, randomized, multicenter, double-masked, active treatment-controlled trial. Participants included treatment-naive patients with subfoveal nAMD and PEDs at baseline; intervention arms were pooled for analysis (n = 586). The HARBOR study began in July 2009 and was completed in August 2012, and the post hoc analyses were conducted between October 2016 and May 2018. INTERVENTIONS: Intravitreal injections of ranibizumab, 0.5 mg and 2.0 mg, administered monthly or on an as-needed basis over 24 months. MAIN OUTCOMES AND MEASURES: Post hoc analyses of flattened PED frequency at month 1, univariate and multivariable analysis of patient and ocular characteristics at baseline and PED status at month 1, and total number of ranibizumab injections received stratified by PED status at month 1. RESULTS: A total of 35.5% of patients (208 of 586) with PED at baseline achieved a flattened PED after a single ranibizumab injection. An additional 17.3% subsequently achieved a flattened PED at month 2. Univariate analysis identified an association between older age, lower PED height, and lower subretinal fluid thickness with PED flattening after a single injection. Multivariable analysis identified PED height as a factor associated with this anatomical outcome. Best-corrected visual acuity scores were not superior based on PED flattening at month 1. On average, patients in the as-needed arm who achieved a flattened PED after a single ranibizumab injection required fewer injections by month 24 vs patients whose PED remained present at month 1 (11.0 vs 14.2; difference, 3.3; 95% CI, 1.9-4.6; P < .001). CONCLUSIONS AND RELEVANCE: In this group of treatment-naive patients with PED from nAMD, after the initial ranibizumab injection approximately one-third and after the second injection approximately one-half had flattened PEDS, although visual outcomes were not superior among those that did vs did not have flattening. The findings suggest flattening may serve as a marker for less intensive as-needed injection frequencies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00891735.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Javaheri M, Hill L, Ghanekar A, et al. Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial. JAMA Ophthalmol. 2021. PMID: 33331859. doi:10.1001/jamaophthalmol.2020.5130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。